PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

Cancer immunotherapy focuses on inhibitors of checkpoint proteins, such as programmed death ligand 1 (PD-L1). Unlike RAS-mutated lung cancers, EGFR mutant tumors have a generally low response to immunotherapy. Because treatment outcomes vary by EGFR allele, intrinsic and microenvironmental factors m...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cell Rep
Main Authors: Ghosh, Soma, Nataraj, Nishanth Belugali, Noronha, Ashish, Patkar, Sushant, Sekar, Arunachalam, Mukherjee, Saptaparna, Winograd-Katz, Sabina, Kramarski, Lior, Verma, Aakanksha, Lindzen, Moshit, Garcia, Diana Drago, Green, Joseph, Eisenberg, Galit, Gil-Henn, Hava, Basu, Arkaprabha, Lender, Yan, Weiss, Shimon, Oren, Moshe, Lotem, Michal, Geiger, Benjamin, Ruppin, Eytan, Yarden, Yosef
פורמט: Artigo
שפה:Inglês
יצא לאור: Cell Press 2021
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8170369/
https://ncbi.nlm.nih.gov/pubmed/34038737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2021.109181
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים